Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Jens D Hove, MD,PHD
Modality
protein_peptide
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06423599CT.gov Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Systolic Heart Failure
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Semaglutide (this asset) | Jens D Hove, MD,PHD | P2/3 | B · 57 |
| Pertuzumab | Medstar Health Research Institute | P2 | B |
| Trastuzumab Emtansine | Medstar Health Research Institute | P2 | B |
| Trastuzumab | Medstar Health Research Institute | P2 | B |
| Eplerenone | Karolinska Institutet | P2 | CCC |
| Ketone Monoester | The University of Texas Health Science Center at San Antonio | Early P1 | C |
| Bortezomib | Oregon Health and Science University | Unk | D |
| Dapagliflozin | National Medical Research Center for Cardiology, Ministry of Health of Russian Federation | N/A | D |
Other indications for Semaglutide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metabolic Disease | — | P4 | A · 81 |
| Polycystic Ovary Syndrome | — | P4 | BBB · 79 |
| Type 2 Diabetes Mellitus | — | P4 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Semaglutide in Systolic Heart Failure. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/semaglutide-systolic-heart-failure
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →